Dr. Chapa’s Clinical Pearls. NEW SPECIAL REPORT: FDA SAFETY NOTICE for Veozah
Sep 13, 2024
A recent FDA safety communication raises alarms about Veozah, highlighting a rare but serious liver injury associated with the medication. The discussion emphasizes the importance of monitoring for adverse effects and proactive steps healthcare providers must take. Additionally, the hosts express gratitude to their audience for their continued support, reinforcing their commitment to providing vital updates and information regarding drug safety.
AI Snips
Chapters
Transcript
Episode notes
Single Case Triggers FDA Alert
- A single patient case of serious liver injury prompted an FDA safety communication on Veozah (fezolinetant).
- This highlights the importance of adverse event reporting for new medications to ensure patient safety.
Liver Monitoring Schedule for Veozah
- Monitor liver function monthly for the first three months and then at six and nine months on Veozah.
- Patients must have baseline and regular liver tests to detect early signs of liver injury.
Stop Medication If Symptoms Appear
- Stop Veozah immediately if patients experience symptoms like fatigue, itching, jaundice, or abdominal pain.
- Don't wait for blood test results; prompt discontinuation can prevent severe liver damage.